Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00583999 · ClinicalTrials.gov registry record

The Role of Leptin Receptors in NASH

A clinical trial of Metabolic Syndrome and Nonalcoholic Steatohepatitis, sponsored by University of California, Davis.

Completed
Registry status
104
Enrollment target
1
Study location

NCT00583999: Completed study of Metabolic Syndrome and Nonalcoholic Steatohepatitis, sponsored by University of California, Davis.

NCT00583999 is a study of Metabolic Syndrome and Nonalcoholic Steatohepatitis that has completed, run by University of California, Davis. The registered enrollment target is 104 participants, below the 1,204-participant average among 102 other Metabolic Syndrome trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00583999, a study of Metabolic Syndrome and Nonalcoholic Steatohepatitis, has completed, sponsored by University of California, Davis.

COMPLETED
Registry status
104 participants
Enrollment target
1
Study location

Study Summary

NAFLD is a spectrum of liver diseases associated with varying degrees of hepatic steatosis, inflammation, and in some cases, fibrosis. NAFLD is a common observation in all demographics, but the prevalence of NAFLD and nonalcoholic steatohepatitis (NASH) is especially high in the morbidly obese population. Leptin is a cytokine that is encoded by the ob gene and primarily secreted by adipose tissue. The production of serum leptin increases with progressive obesity. Because of this observation, there has been significant interest in potential role of leptin in NAFLD. Our hypothesis is that we will find increased hepatic leptin and leptin receptor expression as the degree of hepatic injury worsens in NAFLD.

Interventions

  • OTHER no interventions, only regular blood-draw

Study Locations (1)

California

  • UC Davis Medical Center - Sacramento

Trial Details

FieldValue
Enrollment Target 104 participants
Start Date 2006-01
Est. Completion 2009-06
University of California, Davis

657 total trials

What the finished NCT00583999 record still lists

NCT00583999 is an observational study that tracks outcomes without assigning an intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, below the 1,204-participant average among 102 other Metabolic Syndrome trials with a reported enrollment target (91% lower).

The record links to 2 conditions, with Metabolic Syndrome appearing as the primary indexed condition, and to 1 intervention - of which no interventions, only regular blood-draw is the first listed.

NCT00583999 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT00583999 about?

NCT00583999 is a clinical study titled "The Role of Leptin Receptors in NASH". NAFLD is a spectrum of liver diseases associated with varying degrees of hepatic steatosis, inflammation, and in some cases, fibrosis. NAFLD is a common observation in all demographics, but the prevalence of NAFLD and nonalcoholic steatohepatitis (NASH) is especially high in the morbidly obese popul...

What is the current status of trial NCT00583999?

This trial is currently completed. The enrollment target is 104 participants. The study started on 2006-01. Estimated completion is 2009-06.

What conditions does trial NCT00583999 study?

This clinical trial studies the following conditions: Metabolic Syndrome, Nonalcoholic Steatohepatitis.

What interventions are being tested in trial NCT00583999?

The interventions under investigation include: no interventions, only regular blood-draw (OTHER).

Who is sponsoring clinical trial NCT00583999?

This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00583999 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Metabolic Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00583999's enrollment target sits among peer trials

104 31st of 102 higher than 72 of 102 other Metabolic Syndrome trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Metabolic Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03403686 · 104 participants

    Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)

  • NCT04228367 · 104 participants · NA

    JuggerStitch Post Market Clinical Follow-up Study

  • NCT04268849 · 104 participants · Phase 3

    Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient

  • NCT04390724 · 104 participants

    Optimizing Y90 Therapy for Radiation Lobectomy

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00583999, the US trial registry maintained by the National Library of Medicine. NCT00583999 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.